INmune Bio, Inc. (NASDAQ:INMB) Receives $8.00 Consensus Target Price from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus rating of “Hold” from the six analysts that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.00.

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th.

INmune Bio Stock Performance

Shares of INMB opened at $1.42 on Friday. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $11.64. The company has a market capitalization of $37.74 million, a price-to-earnings ratio of -0.85 and a beta of 1.04. The firm has a 50-day simple moving average of $1.35 and a 200-day simple moving average of $1.50.

INmune Bio (NASDAQ:INMB) last announced its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04.

Institutional Investors Weigh In On INmune Bio

Hedge funds have recently added to or reduced their stakes in the company. Quadrature Capital Ltd acquired a new stake in INmune Bio in the fourth quarter valued at about $26,000. Intech Investment Management LLC acquired a new stake in INmune Bio in the second quarter valued at about $26,000. Cary Street Partners Financial LLC acquired a new stake in INmune Bio in the third quarter valued at about $29,000. Independent Advisor Alliance acquired a new stake in INmune Bio in the third quarter valued at about $30,000. Finally, Squarepoint Ops LLC acquired a new stake in INmune Bio in the third quarter valued at about $30,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.